Status:
RECRUITING
Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Renal Replacement Therapy for Acute Kidney Injury in ICU
Eligibility:
All Genders
18+ years
Brief Summary
The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AK...
Detailed Description
Tumor lysis syndrome (TLS) is a common and life-threatening complication in patients with hematologic malignancies, characterized by severe metabolic imbalances due to rapid tumor cell destruction. Th...
Eligibility Criteria
Inclusion
- Adults aged ≥18 years.
- Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
- Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
- Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.
Exclusion
- Patient or family opposition to data collection for research purposes.
- Incomplete medical records that preclude data extraction.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06889974
Start Date
July 1 2025
End Date
July 1 2027
Last Update
January 9 2026
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Angers
Angers, France
2
Hôpital Pellegrin
Bordeaux, France
3
Hôpital la cavale blanche
Brest, France
4
CHU Dupuytren 1
Limoges, France